102 related articles for article (PubMed ID: 23810672)
1. A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.
Shahani VM; Ball DP; Ramos AV; Li Z; Spagnuolo PA; Haftchenary S; Schimmer AD; Trudel S; Gunning PT
Bioorg Med Chem; 2013 Sep; 21(17):5618-28. PubMed ID: 23810672
[TBL] [Abstract][Full Text] [Related]
2. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
Wang X; He Q; Wu K; Guo T; Du X; Zhang H; Fang L; Zheng N; Zhang Q; Ye F
Eur J Med Chem; 2019 Oct; 179():218-232. PubMed ID: 31254923
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
Page BD; Croucher DC; Li ZH; Haftchenary S; Jimenez-Zepeda VH; Atkinson J; Spagnuolo PA; Wong YL; Colaguori R; Lewis AM; Schimmer AD; Trudel S; Gunning PT
J Med Chem; 2013 Sep; 56(18):7190-200. PubMed ID: 23968501
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
6. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
Page BD; Khoury H; Laister RC; Fletcher S; Vellozo M; Manzoli A; Yue P; Turkson J; Minden MD; Gunning PT
J Med Chem; 2012 Feb; 55(3):1047-55. PubMed ID: 22148584
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
8. Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1.
Gupta SC; Phromnoi K; Aggarwal BB
Biochem Pharmacol; 2013 Apr; 85(7):898-912. PubMed ID: 23279849
[TBL] [Abstract][Full Text] [Related]
9. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation and docking studies of 4-amino-tetrahydroquinazolino[3,2-e]purine derivatives.
Verones V; Flouquet N; Farce A; Carato P; Leonce S; Pfeiffer B; Berthelot P; Lebegue N
Eur J Med Chem; 2010 Dec; 45(12):5678-84. PubMed ID: 20884092
[TBL] [Abstract][Full Text] [Related]
11. Exploring the purine core of 3'-C-ethynyladenosine (EAdo) in search of novel nucleoside therapeutics.
Hulpia F; Balzarini J; Schols D; Andrei G; Snoeck R; Van Calenbergh S
Bioorg Med Chem Lett; 2016 Apr; 26(8):1970-2. PubMed ID: 26965865
[TBL] [Abstract][Full Text] [Related]
12. Lignopurines: a new family of hybrids between cyclolignans and purines. Synthesis and biological evaluation.
Castro MÁ; Miguel del Corral JM; García PA; Rojo MV; Bento AC; Mollinedo F; Francesch AM; San Feliciano A
Eur J Med Chem; 2012 Dec; 58():377-89. PubMed ID: 23153810
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
[TBL] [Abstract][Full Text] [Related]
14. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
15. Purine derivatives of 1,2-disubstituted cyclohexane analogues of nucleosides.
Terán C; Santana L; Uriarte E; Viña D; De Clercq E
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):787-9. PubMed ID: 14565279
[TBL] [Abstract][Full Text] [Related]
16. 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.
Imbach P; Capraro HG; Furet P; Mett H; Meyer T; Zimmermann J
Bioorg Med Chem Lett; 1999 Jan; 9(1):91-6. PubMed ID: 9990463
[TBL] [Abstract][Full Text] [Related]
17. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of novel acyclic versions of Neplanocin A.
Wu Y; Hong JH
Arch Pharm (Weinheim); 2005 Nov; 338(11):517-21. PubMed ID: 16281309
[TBL] [Abstract][Full Text] [Related]
19. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells.
Tuncbilek M; Guven EB; Onder T; Cetin Atalay R
J Med Chem; 2012 Apr; 55(7):3058-65. PubMed ID: 22409771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
